This browser is no longer supported

Please switch to a supported browser to continue using this website.
Consider using the latest version of Google Chrome or Microsoft's Edge to view this website.

Five Year Summary

All figures are in US$ million unless stated otherwise

2020-21
Constant Currency(1)
 
2020-21
Reported(2)
 
2019-20
Reported
 
2018-19
Reported
2017-18 
Reported
2016-17 
Reported 
Total Operating Revenue 10,026 10,310  9,151  8,539  7,915  6,947
Sales Revenue 9,705 9,980  8,797  8,205   7,588  6,616
R&D Investment 969 1,001  922  832   702  667
Profit before Income Tax Expense 2,872 2,963  2,573  2,341   2,281  1,690
Net profit after tax 2,307 2,375  2,103  1,919  1,729  1,337
Net cash inflow from Operating Activities   3,622  2,448  1,644   1,902  1,247
Capital investment   1,667  1,367  1,285   992  861
Return on Invested Capital (%)   21.2  21.6  24.3   25.9  24.5
Basic earnings per share ($)   5.221  4.633  4.236   3.822  2.937
Dividend per share ($)   2.22  2.02  1.850   1.720  1.360

 

(1) Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further details please refer to CSL's Financial Statements for the Full Year ended 2021 (Directors' Report).
(2) The Group's reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(3) 2016 figure includes the gain on acquisition of Novartis' global influenza vaccine business of US$176.1 million.

 

Introduction to CSL

See how we are driven by our promise.

Learn More

Board and Management

View our Board and Management here.

Learn More

Corporate Governance

View our corporate governance here.

Learn More